Effects of Oxytocin on Negative Symptoms and Social Cognition in Schizophrenia and Its Possible Mechanisms
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, negative symptoms, oxytocin
Eligibility Criteria
Inclusion criteria were:
- aged between 18 and 55 years;
- DSM-IV diagnosis of schizophrenia, acute schizophreniform disorder, or schizoaffective disorder.
Exclusion criteria were:
- presence of other psychiatric diagnoses (e.g., depression);
- active misuse of substance or alcohol;
- intellectual disability (IQ < 70);
- a history of neurological disorder.
Sites / Locations
- Shanghai Mental Health Center
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
schizophrenia with oxytocin
schizophrenia with Placebo
Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.